Tag: malignant melanoma

Recent Trend: Melanoma Mortality Declining Rapidly

Declining trends in melanoma death rates accelerated from 2014 to 2018 in the United States, even as incidence rates increased for both males and females, according...

Latest FDA Pembrolizumab Approval Expands Label to Cutaneous SCCs

The Food and Drug Administration has approved pembrolizumab (Keytruda) monotherapy for locally advanced cutaneous squamous cell carcinoma (cSCC) that can’t be cured by surgery or...

Immunotherapy Combo Now Approved for First-Line Mesothelioma in EU

Combination therapy with the immunotherapies nivolumab (Opdivo) and ipilimumab (Yervoy) is now approved in the European Union for the first-line treatment of adults with unresectable...

Many Sunscreens Have a Carcinogen, Pharmacy Tells FDA

Summer is around the corner, and with the pandemic waning for many, the CDC encourages people to spend more time unmasked outdoors. But protecting yourself...

Ellie Guardino, MD, Battled Others’ Cancer, Has Died of Her Own

The oncology community is mourning the loss of Ellie Guardino, MD, PhD, a compassionate physician-scientist who fought through her own diagnosis of metastatic melanoma while...

Made-to-Order TILs Effective Against Metastatic Melanoma

In just over one third of patients with metastatic melanoma who had experienced disease progression while receiving multiple prior lines of therapy, including immunotherapy and...

Chronic Immune-Related Adverse Events Likely Common After Anti-PD-1 Therapy for Melanoma

NEW YORK (Reuters Health) – Chronic immune-related adverse events (irAEs) associated with anti-programmed cell death-1 (PD-1) therapy for melanoma were more common than previously thought...

Fecal Transplant Overcomes Resistance to Immunotherapy

For some patients with advanced melanoma whose conditions had stopped responding to immunotherapy, response was restored after treatment with fecal transplants. The material for the...

ICI for Cancer Ups Cardiac Event Risk: Danish Data

Immune checkpoint inhibitors (ICIs) increase the risk of cardiac events, including fatal heart attack and stroke, in patients with cancer, an analysis of Danish national...

Beta-Blocker May Improve Melanoma Treatment Response

Response rates were high without dose-limiting toxicities in a small phase 1 study that evaluated the addition of propranolol to pembrolizumab in treatment-naive patients with...

Mitotic Rate Makes Comeback as Melanoma Prognosticator

Mitotic rate, properly applied, has a prognostic impact in melanoma comparable to that of lesional ulceration, Mohammed Kashani-Sabet, MD, reported at a virtual forum on...

Real-World Results With Checkpoint Inhibitors Inferior to CT Data

Real-world survival outcomes for cancer patients on immune checkpoint inhibitors (ICIs) are inferior to outcomes reported in patients on clinical trials of ICIs, according to research...

New Technologies Show Promise for Treating Pigmented Lesions

Picosecond and nanosecond lasers are far more effective for treating individual lentigines, compared with other types of devices, but ultrashort pulses carry a higher risk...

High TMB Predicts Response to Pembrolizumab

Tissue tumor mutation burden (tTMB) has been under study for some time as a biomarker that could predict which patients are most likely to respond...

Vitamin D Tied to Lower Risk for Immunotherapy-Induced Colitis

Taking vitamin D before starting immune checkpoint inhibitor (ICI) therapy may decrease the risk for treatment-related colitis, say researchers in an article published online on...

Cancer Deaths Rise After Pandemic, Single RT Underused

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s  Coronavirus Resource Center. Here are the most important stories that Medscape Oncology’s editors picked...

COMMENTARY: Dermatologist First, Businessman Second: Life During COVID-19

What your doctor is reading on Medscape.com: APRIL 15, 2020 — Monday 8:00 AM. Standing in the Stop & Shop parking lot,...

Defer Nonurgent Skin Cancer Care During Pandemic

Amid the COVID-19 pandemic, defer therapeutic lymphadenectomy for stage III melanoma and opt instead for treatment with checkpoint or BRAF/MEK inhibitors, except when metastatic nodes are threatening...

Encorafenib Now Approved for BRAF-Positive Colorectal Cancer

The targeted agent encorafenib (Braftovi, Array BioPharma, now part of Pfizer) has been approved by the US Food and Drug Administration (FDA) for use in...

Side Effects From Immune Checkpoint Inhibitors Vary by Regimen in Advanced Melanoma

NEW YORK (Reuters Health) – Some immune-checkpoint inhibitor (ICI) regimens for advanced melanoma carry a lower risk of immune-related adverse events (irAEs) than others, according...